Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 Results assessing the pharmacokinetic-pharmacodynamic relationships of sarilumab exposure with key efficacy, and safety endpoints in patients with polymyalgia rheumatica, presented at the ACR Convergence 2023.
05 Oct 2023 Results assessing efficacy of Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper published in the New England Journal of Medicine
03 Jun 2023 Results of post-hoc analysis assessing the proportion of patients achieving sustained remission up to week 52 from week 16 and from week 24, presented at the 24th Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com